Received: 10 October 2019
Accepted: 3 January 2020
First Online: 28 January 2020
Ethics approval and consent to participate
: The study was designed as a prospective cohort study and approved by the local ethics committee (Landesärztekammer des Saarlandes; Ref. ID: 199/09). Written informed consent was obtained from all patients being included in this study.
: Not applicable.
: MK received speaker fees from Fresenius, Baxter, Mitsubishi Pharm, Daiichi Sankyo, Cytosorbents. For the remaining authors none were declared.